Eur Heart J:更多的证据肯定了他汀类预防静脉血栓的疗效!

2017-05-29 sunshine2015 来宝网

莱斯特大学和布里斯托尔大学的研究人员已经发现进一步的证据表明,他汀类可以“显著降低”身体某些部位血液凝固的发生。



更多关于他汀类预防静脉血栓栓塞的证据】莱斯特大学和布里斯托尔大学的研究人员已经发现进一步的证据表明,他汀类可以“显着降低”身体某些部位血液凝固的发生

研究团队分析了以前对胆固醇降低药物进行的几项研究,发现该药物可能在降低静脉血栓栓塞(VTE)的复发风险中起潜在作用。

该研究由NIHR应用健康研究与护理(CLAHRC)东米德兰兹领导力协作组织支持,并在欧洲心脏杂志上发表。

它遵循同一研究小组1月发表的类似研究报告,该研究小组建议他汀类药物将病情的威胁降低15%至25%。

谈到最新的研究报告,共同研究人员Kamlesh Khunti教授,莱斯特大学初级保健糖尿病血管医学教授,NIHR CLAHRC East Midlands主任和莱斯特糖尿病中心联席主任说:“有建议他汀可能在预防VTE中起潜在作用,但证据不一致。”

“我们想进一步探索这个问题,将所有研究结合在一起,以评估他汀类药物与复发性VTE之间的关系。重要的是,我们可以就此情况尽可能的了解这种疾病,因为它被认为每六秒杀死一个人。

“虽然严重,但是可以完全避免大多数血块,并且得到适当的照顾,但是治疗对英国的卫生服务造成了相当大的经济负担,因为它被认为花费大约6.4亿英镑来管理病情。”

在此过程中,对8项研究进行了汇总分析,其中涉及103,500多名参与者,其基于他汀类药物和VTE。

来自布里斯托尔大学临床科学学院肌肉骨骼研究组的首席研究员Setor Kunutsor博士说:“虽然我们的研究还没有发现VTE的原因,但是他们在处理时会强调他汀类药物治疗的潜在作用条件。

“我们的研究显示积累的证据表明,他汀类可能在VTE的一级和二级预防中起着潜在的作用。”

希望这一发现可能会导致新的指导方针和扩大治疗的使用,这已经在心血管疾病预防中确立。

位于莱斯特综合医院的莱斯特糖尿病中心是国际糖尿病研究与教育中心。这是莱斯特大学医院NHS信托基金和莱斯特大学之间的合作伙伴关系,由Khunti教授和Melanie Davies教授领衔。

原始出处:

Setor K. Kunutsor, Samuel Seidu and Kamlesh Khunti. Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. Eur Heart J (2017) 38 (20): 1608-1612. DOI: https://doi.org/10.1093/eurheartj/ehx107.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1697467, encodeId=c712169e46713, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Nov 11 10:20:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955286, encodeId=221719552865e, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Aug 28 00:20:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356298, encodeId=0bec135629857, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 31 11:20:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562543, encodeId=e3511562543dc, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed May 31 11:20:00 CST 2017, time=2017-05-31, status=1, ipAttribution=)]
    2017-11-11 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1697467, encodeId=c712169e46713, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Nov 11 10:20:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955286, encodeId=221719552865e, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Aug 28 00:20:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356298, encodeId=0bec135629857, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 31 11:20:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562543, encodeId=e3511562543dc, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed May 31 11:20:00 CST 2017, time=2017-05-31, status=1, ipAttribution=)]
    2017-08-28 xue8602
  3. [GetPortalCommentsPageByObjectIdResponse(id=1697467, encodeId=c712169e46713, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Nov 11 10:20:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955286, encodeId=221719552865e, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Aug 28 00:20:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356298, encodeId=0bec135629857, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 31 11:20:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562543, encodeId=e3511562543dc, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed May 31 11:20:00 CST 2017, time=2017-05-31, status=1, ipAttribution=)]
    2017-05-31 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1697467, encodeId=c712169e46713, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sat Nov 11 10:20:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955286, encodeId=221719552865e, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Aug 28 00:20:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356298, encodeId=0bec135629857, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed May 31 11:20:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562543, encodeId=e3511562543dc, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed May 31 11:20:00 CST 2017, time=2017-05-31, status=1, ipAttribution=)]
    2017-05-31 slcumt

相关资讯

Gastroenterology:他汀类药物在结肠癌患者生存中的应用

他汀类药物与结肠癌风险降低相关,对于BMP通路完整或KRAS突变患者其效果更为显著,该结果还需要进一步的临床试验确证

JAMA Inter Med:他汀类预防心血管疾病?到底“靠不靠谱”?

根据一项新的研究,参加临床试验的老年患者的数据分析显示,当他汀类药物开始用于老年高血压和中等高胆固醇患者进行一级预防时,并未在所有原因死亡或冠心病事件预防中得到益处。

PLoS One:早期慢性肾病患者使用他汀类药物:利 or 弊?

血脂异常可能会加速CKD进展,使用他汀类药物有助于改善肾功能,但CKD 患者使用他汀类药物的适应证尚不十分明确。近日,韩国嘉泉大学(Gachon University)的Ji Yong Jung博士研究小组在 PLoS ONE 发表的研究表明,“早期慢性肾脏病(CKD)患者(1-3期,估计肾小球滤过率≥ 30 ml/min/1.73 m2)服用他汀类药物可延缓肾功能下降,降低全因死亡率。”该回顾性

他汀类药物治疗可降低AS+PsA患者的心血管风险和总死亡率

根据美国风湿病学会年会上提交的调查结果显示,使用他汀类药物可以让强直性脊柱炎+银屑病关节炎患者的死亡率下降32%。 Amar Oza博士和同事们对2904例强直性脊柱炎(AS)+银屑病关节炎(PsA)患者进行了研究,研究他汀类药物对这类患者的生存益处。 平均随访时间为5.3年,他汀类使用者中死亡人数为271例;对照组5.15年的随访期间内,死亡人数为376例。他汀类药物使用组的死亡率为

JAMA Cardiol:心脏病发作出院后高强度他汀类药物不能停

根据JAMA心脏病学杂志发表的一项研究,住院治疗心脏病后的患者被给予高强度他汀类药物,在出院后两年,大部分患者没有继续服用高剂量的该药物。

Chest:他汀类药物可降低结核病的发生风险!

由此可见,他汀类药物可降低结核病的发生风险。